Drug Trial Radar · NCT02682238
A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis
Last checked: Nov 20, 2026Latest source record: May 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Mar 8, 2016
Primary completion
Jul 14, 2016
Study completion Oct 4, 2016
Sponsor
- Lead sponsor
- Botanix PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and local tolerability of BBI-4000 15% gel compared with vehicle (placebo) when applied topically once daily in subjects with palmar hyperhidrosis.
Conditions
- Hyperhidrosis
Interventions
BBI-4000, 15%Drug
Vehicle gelOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Treatment Emergent Adverse Events by SeverityTime frame: Baseline visit-Day 42 End of Participation
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
TCR Medical Corporation
San Diego, California
International Dermatology Research, Inc.
Miami, Florida
Shideler Clinical Research Center
Carmel, Indiana
Saint Louis University Dermatology
St Louis, Missouri
Virginia Clinical Research, Inc.
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.